Newron Pharmaceuticals S.p.A. Share Price Deutsche Boerse AG
Stocks
NP5
IT0004147952
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Tradegate
05:36:57 01/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 9.090 EUR | +0.11% |
|
-24.14% | -66.98% |
| Market Cap | 18Cr 20Cr 17Cr 15Cr 29Cr 1.96TCr 29Cr 204.56Cr 79Cr 1TCr 77Cr 75Cr 3.22TCr | P/E 2026 * |
-6.51x | P/E 2027 * | 243x |
|---|---|---|---|---|---|
| Enterprise Value | 19Cr 22Cr 18Cr 17Cr 31Cr 2.12TCr 32Cr 220.67Cr 85Cr 1.08TCr 83Cr 81Cr 3.47TCr | EV / Sales 2026 * |
22.9x | EV / Sales 2027 * | 4.98x |
| Free-Float |
87.16% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| NWRN | Delayed | |
Tradegate
| NP5 | Real-time | |
|
Xetra
| NP5 | Delayed | |
|
CBOE
| 0QOI | Real-time | |
|
Deutsche Boerse AG
| NP5 | Delayed | |
|
Boerse Muenchen
| NP5 | Real-time | |
|
Börse Stuttgart
| NP5 | Delayed |
Last Transcript: Newron Pharmaceuticals S.p.A.
| 1 day | +0.11% | ||
| 1 week | -24.14% | ||
| Current month | -3.08% | ||
| 1 month | -32.05% | ||
| 3 months | -36.92% | ||
| 6 months | -46.47% | ||
| Current year | -66.98% |
| 1 week | 8.2 |  | 11.4 |
| 1 month | 8.2 | | 13.15 |
| Current year | 8.2 | | 33.55 |
| 1 year | 8.2 | | 33.55 |
| 3 years | 4.2 | | 33.55 |
| 5 years | 1 | | 33.55 |
| 10 years | 1 | | 33.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 62 | 15/05/2012 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01/01/2012 |
Filippo Moriggia
COO | Chief Operating Officer | - | 01/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Stefan Weber
BRD | Director/Board Member | 62 | 15/05/2012 |
Gillian Dines
BRD | Director/Board Member | - | 01/04/2023 |
Margarita Chavez
BRD | Director/Board Member | - | 17/04/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.11% | -24.14% | - | - | 20Cr | |
| +4.16% | -0.36% | +49.37% | +94.17% | 7.45TCr | |
| +0.05% | +1.51% | +28.12% | +81.46% | 6.01TCr | |
| -0.73% | +0.18% | +6.81% | +35.79% | 4.82TCr | |
| -0.05% | +0.37% | +41.54% | +36.65% | 4.43TCr | |
| +0.38% | +7.61% | +339.53% | +641.55% | 4.4TCr | |
| +0.18% | +0.26% | +7.41% | +103.45% | 4.16TCr | |
| -0.67% | +0.17% | +7.60% | +46.37% | 3TCr | |
| +4.77% | +6.16% | +36.77% | +22.78% | 2.93TCr | |
| -1.29% | -3.55% | -20.74% | +352.04% | 2.49TCr | |
| Average | +0.77% | +1.53% | +55.16% | +157.14% | 4.41TCr | |
| Weighted average by Cap. | +1.06% | +1.53% | +59.39% | +147.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 84.88L 96.38L 80.42L 72.6L 1.37Cr 92Cr 1.39Cr 9.62Cr 3.7Cr 47Cr 3.62Cr 3.54Cr 151.47Cr | 3.99Cr 4.53Cr 3.78Cr 3.41Cr 6.43Cr 434.05Cr 6.51Cr 45Cr 17Cr 221.89Cr 17Cr 17Cr 711.4Cr |
| Net income | -3Cr -3.41Cr -2.84Cr -2.57Cr -4.84Cr -326.58Cr -4.9Cr -34Cr -13Cr -166.96Cr -13Cr -13Cr -535.27Cr | -19.56L -22.21L -18.53L -16.73L -31.53L -21Cr -31.94L -2.22Cr -85.33L -11Cr -83.41L -81.59L -35Cr |
| Net Debt | 1.42Cr 1.61Cr 1.35Cr 1.22Cr 2.29Cr 154.72Cr 2.32Cr 16Cr 6.2Cr 79Cr 6.06Cr 5.93Cr 253.59Cr | 1.81Cr 2.06Cr 1.72Cr 1.55Cr 2.92Cr 197.43Cr 2.96Cr 21Cr 7.91Cr 100.93Cr 7.73Cr 7.56Cr 323.58Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/26/01 | €8.800 | -3.08% | 3 |
| 30/26/30 | €9.080 | +10.73% | 400 |
| 29/26/29 | €8.200 | 0.00% | 0 |
| 28/26/28 | €8.200 | -21.90% | 8,300 |
| 25/26/25 | €10.50 | -9.48% | 0 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NWRN Stock
- NP5 Stock
Select your edition
All financial news and data tailored to specific country editions
